13 May 2020 - Sunovion Pharmaceuticals today announced that it has withdrawn the new drug applications for dasotraline, a novel dopamine and norepinephrine re-uptake inhibitor, for the treatment of moderate-to-severe binge eating disorder and attention deficit hyperactivity disorder.

While Sunovion considers dasotraline to be a promising, novel treatment for binge eating disorder and attention deficit hypercativity disorder, the Company believe that further clinical studies would be needed to support a regulatory approval for dasotraline in these indications.

Sunovion consistently evaluates and prioritises its pipeline of potential medicines. At this time, the Company has decided not to pursue any further development of dasotraline.

Read Sunovion Pharmaceuticals press release